Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
536.1 USD | -1.33% | +1.66% | +15.79% |
04-24 | McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3 | MT |
04-24 | McKesson Corporation Declares Quarterly Dividend, Payable on June 3, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.23 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The firm trades with high earnings multiples: 24.35 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.79% | 70.45B | C+ | ||
+2.09% | 25.03B | C+ | ||
-3.28% | 8.05B | C | ||
+7.95% | 8.29B | B | ||
-20.48% | 7.97B | B- | ||
+15.26% | 4.25B | B+ | ||
-1.24% | 4.04B | B- | ||
-3.02% | 3.86B | B | ||
+21.10% | 3.61B | C+ | ||
+8.07% | 3.31B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCK Stock
- Ratings McKesson Corporation